Answers are grounded in this paper and cite their sources.
= 0.000025). This study showed that dinutuximab beta, particularly in combination with standard chemotherapy, offers a promising approach to improve outcomes for high-risk Ewing sarcoma patients, providing a more effective alternative to current treatments.
No takes yet. Share an insight, caveat, or question.
Frapolli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: